Switching from concomitant therapy to tafluprost/timolol fixed combination

Area of Science:

• Ophthalmology
• Glaucoma Research
• Pharmacology

Background:

• Primary open-angle glaucoma (POAG) management often involves multiple topical medications.
• Adherence and patient preference are crucial for long-term treatment success.
• Tafluprost and timolol are commonly prescribed prostaglandin analog and beta-blocker, respectively.

Purpose of the Study:

• To evaluate the efficacy and safety of switching from separate tafluprost and timolol eye drops to a fixed combination (TTFC).
• To assess intraocular pressure (IOP) control, safety, and patient acceptance of TTFC.

Main Methods:

• A prospective study enrolled 28 patients with POAG previously treated with separate tafluprost and timolol.
• Patients were switched to TTFC without a washout period.
• Evaluated IOP, blood pressure, pulse rate, ocular signs, and patient-reported outcomes over 8 weeks.

Main Results:

• TTFC maintained stable IOP compared to baseline.
• No significant changes in pulse rate or systolic blood pressure were observed.
• Diastolic blood pressure decreased significantly at 8 weeks; ocular adverse events were minimal and mostly resolved.

Conclusions:

• Switching to TTFC provides comparable IOP control to separate administration in compliant patients.
• TTFC is safe and well-tolerated, with a high level of patient acceptance.
• TTFC offers a convenient alternative for glaucoma management.